Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The study shows that RADA-F6 peptide with pH-responsive self-assembling nature can be effectively used as a drug delivery system for the sustained release of a potent anticancer drug 5-fluorouracil (5-FU) at basic pH. As 5-FU contains the aromatic pyrimidine ring, RADA-F6 system is suitable for entrapping an aromatic drug due to effective π-π stacking with phenylalanine and be able to show better controlled release behavior. The stability and controlled release nature of RADA-F6 in different conditions followed by 5-FU entrapment at in silico conditions was confirmed by molecular dynamics simulation taking RADA-16 as control. Cytotoxicity of the drug-loaded RADA-F6 was measured by MTT assay and cellular uptake by confocal microscopy. Physicochemical characterization and further Western blot analysis and flow cytometric studies confirm that RADA-F6 can be successfully used as an efficient vector for pH-sensitive, controlled 5-FU delivery system.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087806 | PMC |
| http://dx.doi.org/10.2147/IJN.S104707 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ion channels in NK cells: signaling and functions.
J Leukoc Biol
September 2025
Laboratory of Immunobiology and Ionic Transport Regulation, Centro Universitario de Investigaciones Biomédicas, Universidad de Colima, Av. 25 de Julio 965, Villa de San Sebastián, 28045 Colima, México.
Ion channels are integral membrane proteins which facilitate rapid transport of small ions into and out of the cell and between organelles and cytosol. Cytolytic lymphocytes including natural killer (NK) cells principally kill virus-infected and cancer cells by releasing cytolytic granules within the immunological synapse, formed between target and effector cells. This process strongly depends on Ca2+ signaling, which in human NK cells is controlled by the phospholipase C (PLCγ)/inositol-1,4,5-triphospate receptor (IP3R)/calcium release-activated calcium channel (CRAC) axis.
View Article and Find Full Text PDFLipidic nanocarriers for the treatment of schizophrenia: progress and prospects of solid lipid nanoparticles and nanostructured lipid carriers.
J Biomater Sci Polym Ed
September 2025
LJ Institute of Pharmacy, Department of Pharmaceutical Technology, LJK University, Ahmedabad, India.
Schizophrenia is a persistent and incapacitating neuropsychiatric condition that presents considerable obstacles regarding pharmacological administration and therapeutic effectiveness. Lipidic nanocarriers, including Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs), have emerged as effective drug delivery vehicles for enhancing the bioavailability, stability, and controlled release of antipsychotic medicines. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) have several benefits, such as improved drug loading capacity, less systemic adverse effects, and superior efficacy in traversing the blood-brain barrier compared to conventional formulations.
View Article and Find Full Text PDFElectrically Triggered Fluorescein and Dexamethasone Release from Conducting Polymer Hydrogels.
Tissue Eng Part A
September 2025
Department of Chemical and Materials Engineering, Faculty of Engineering, The University of Auckland, Auckland, New Zealand.
Spatially and temporally controlled drug delivery is an important field to address the limitations of conventional pharmaceutical administration. While many effective controlled drug delivery systems exist, the repertoire of systems that additionally present a beneficial mechanical environment to cells remains scarce. To address this, a comprehensive release study of fluorescein as a model drug, and the corticosteroid dexamethasone, from poly(-isopropylacrylamide)/polypyrrole (pNIPAM/PPy) conducting polymer hydrogels is presented within this study.
View Article and Find Full Text PDFAdjuvant potential of metformin with standard anti-seizure medications in persons with active epilepsy: a randomised controlled trial.
Naunyn Schmiedebergs Arch Pharmacol
September 2025
Dept. of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.
The purpose of this study was to investigate the efficacy and safety of add-on metformin treatment in persons with active epilepsy (a-PWE). This is a single-centric, double-blind, placebo-controlled trial randomised a-PWE (1:1) to receive either metformin (extended-release 500 mg) or matching placebo for 6 months along with background antiseizure medications. Primary outcome was percentage change in seizure frequency/month, and secondary outcomes were 50% responder rate, serum mTOR expression, and serum total antioxidant capacity (TAC), body composition analysis, quality of life (QOL), and safety assessment.
View Article and Find Full Text PDFNext-generation nanocarriers for colorectal cancer: passive, active, and stimuli-responsive strategies for precision therapy.
Biomater Sci
September 2025
Department of Pharmaceutics and Pharmaceutical Technology, College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates.
Colorectal cancer (CRC) remains a major global health burden, necessitating more effective and selective therapeutic approaches. Nanocarrier-based drug delivery systems offer significant advantages by enhancing drug accumulation in tumors, reducing off-target toxicity, and overcoming resistance mechanisms. This review provides a comprehensive overview of recent advancements in nanocarriers for CRC therapy, including passive targeting the enhanced permeability and retention (EPR) effect, and active targeting strategies that exploit specific tumor markers using ligands such as antibodies, peptides, and aptamers.
View Article and Find Full Text PDF